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Summary
  Introduction:  There is a growing body of data concerning significant interactions between markers of inflam-
mation and cardiovascular diseases such as hypertension accompanied by elevated levels of pla-
sma C-reactive protein (CRP). Therefore CRP is thought to be an independent risk factor of car-
diovascular diseases.
  Material/Methods:  The aim of this study was to evaluate the effects of antihypertensive therapy (perindopril, biso-
prolol and combined therapy) on plasma CRP concentration in 67 subjects with mild or mode-
rate hypertension who have been treatment-naive and otherwise healthy.
  Results:  The results show a correlation between CRP level and blood pressure values. BP reduction was 
associated with a decrease in CRP concentration. The CRP-lowering effect of perindopril and 
bisoprolol was comparable and the degree of reduction might reflect their similar influence 
on blood pressure. Combined treatment influenced the CRP level to a greater extent than both 
monotherapies.
  Conclusions:  Plasma CRP level was lowered by antihypertensive therapy independently of the drug applied. 
The CRP level did not normalize completely in moderate hypertensive patients.
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Streszczenie
  Wstęp:  Wyniki wielu ostatnio opublikowanych badań ukazują istotne związki między wskaźnikami stanu 
zapalnego a chorobami układu sercowo-naczyniowego. Stężenie CRP jest uważane za niezależ-
ny czynnik ryzyka rozwoju chorób układu krążenia i jest ono zwiększone między innymi u cho-
rych na nadciśnienie tętnicze.
 Materiał/Metody:  Celem badania była ocena wpływu leczenia obniżającego ciśnienie tętnicze (za pomocą perin-
doprilu, bisoprololu i leczenia skojarzonego) na stężenie CRP w osoczu chorych na nadciśnie-
nie tętnicze łagodne i umiarkowane.
  Wyniki:  Zaobserwowano korelację między stężeniem CRP a wartościami ciśnienia tętniczego. Terapia 
przeciwnadciśnieniowa doprowadziła do zmniejszenia stężenia CRP. Leczenie bisoprololem 
i perindoprilem spowodowało porównywalne zmniejszenie stężenia CRP, co prawdopodobnie 
odzwierciedla podobny efekt hipotensyjny obu leków. Leczenie skojarzone bardziej niż każda 
z monoterapii zmniejszało stężenie CRP.
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There is a growing body of data concerning significant in-
teractions between markers of inflammation and cardiova-
scular diseases. Diseases linked to atherosclerosis, such as 
myocardial infarction, stroke or unstable angina, are cha-
racterized by an increase in inflammatory markers, inc-
luding plasma C-reactive protein (CRP). Hypertension is 
accompanied by an elevated level of CRP and other pro-
inflammatory cytokines together with adhesive molecu-
les [2,3,4,31,35].
The Women’s Health Study (WHS), performed on 20,250 
women with high-normal blood pressure, confirmed a si-
gnificant association between the serum CRP level and 
the risk of subsequent hypertension development [33]. 
Convergent results were described by Niskanen et al. [25]. 
It has been shown that increased CRP level (>3 mg/L) in 
comparison with lower values (<1 mg/L) was associated 
with more frequent occurrence of hypertension. In 2004, 
the results of the ATTICA study (with 3,000 subjects) di-
sclosed that patients prone to hypertension had augmented 
immune system reactivity that was expressed, inter alia, by 
increased (30%) levels of CRP (3). However, to date, the-
re are still only a few studies concerning the influence of 
modern antihypertensive therapy on CRP level [9,34,41]. 
A question asked was whether long-lasting cardioselec-
tive beta-adrenolytics were able to affect CRP level with 
effectiveness comparable to ACE-I. Additionally, we so-
ught to evaluate the magnitude of the influence of com-
bined therapy (with bisoprolol and perindopril) on blood 
pressure and CRP level in patients with moderate hyper-
tension. The uniqueness of our study lies in the strict inc-
lusion criteria concerning patients with a normal level of 
lipids (the mean values of lipids were as follows: total cho-
lesterol [TC] 5.11 mmol/L, high density cholesterol [HDL] 
1.25 mmol/L, low density cholesterol [LDL] 3.28 mmol/L, 
triglycerides [TG] 1.5 mmol/L). None of the studies per-
formed so far have referred to total cholesterol level, tho-
ugh its positive correlation with plasma CRP concentra-
tion has been shown.
Unlike in similar studies, the method of 24-hour blood 
pressure monitoring was used to assess blood pressure. 
There is only a single study reported to use this kind of 
BP appraisal [28]. Additionally, to date, there have been 
no studies considering the influence of long-lasting car-
dioselective beta-blockers on CRP level. The studies pu-
blished to date have provided an insight into the effects of 
non-cardioselective beta-blockers such as propranolol and 
carvedilol [24] or short-acting metoprolol [18]. Our study 
presents the influence of bisoprolol as a long-lasting, car-
dioselective beta-blocker, perindopril as a modern ACE-I, 
and combined therapy on blood pressure and CRP level.
MaterIal and Methods
Study population
The study was carried out on 67 subjects divided into 3 gro-
ups (Table 1). The first group included 22 patients with 2nd 
stage (moderate) hypertension, while the second and third 
covered patients with 1st stage (mild) arterial hypertension. 
The control group consisted of 30 normotensive patients.
Hypertension had been recently diagnosed in all subjects, 
none of whom had ever been treated with any antihyper-
tensive drugs. Patients were considered hypertensive if 
  Wnioski:  W trakcie stosowania każdej z terapii przeciwnadciśnieniowych stwierdzono zmniejszenie stę-
żenia CRP. U chorych na umiarkowane nadciśnienie tętnicze nie uzyskano jednak normalizacji 
stężenia CRP.
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following at least four sets of readings (taken at week in-
tervals) and having injuries of retinal arteries correspon-
ding to 1st or 2nd stage arterial hypertension on fundoscopy. 
Additionally, 24-hour ambulatory non-invasive blood pres-
sure monitoring was performed before and after 1-month 
therapy in each patient. Control subjects had a supine sy-
stolic blood pressure lower than 130 mmHg and a diasto-
lic one lower than 85 mmHg. The moderate hypertension 
group was given combined therapy (perindopril 4 mg daily 
plus bisoprolol 5 mg daily, both administered once a day in 
the morning). Patients with mild hypertension were rando-
mized into two groups: those taking perindopril (4 mg once 
a day in the morning) and those taking bisoprolol (5 mg 
in the morning). All patients signed the informed consent.
Exclusion criteria included alcohol or drug abuse, pre-
sence of secondary hypertension, isolated systolic or 3rd 
stage hypertension, kidney, heart, liver or gastrointestinal 
diseases, inflammatory diseases, diabetes mellitus and li-
pid disorders. Patients treated with any drugs influencing 
blood pressure or with an acute or chronic inflammatory 
state were excluded as well as those with endocrine, neu-
rological, haematological and metabolic disturbances or 
cancer history. The study population was comparable in 
gender, age, body mass index, lipid level and smoking hi-
story. Subjects with acute or chronic inflammation were 
excluded on the basis of the physical examination and ba-
sic laboratory tests (complete blood count, CRP, electro-
lytes, transaminases, glucose, creatinine and urinalysis). 
When it was necessary, additional laboratory tests were 
conducted (electrophoresis, oral glucose tolerance test) to-
gether with the radiographic examination (chest and den-
tal x-rays) and the consultation of specialists (such as an 
otolaryngologist). Each patient underwent Doppler ultra-
sound imaging of the renal arteries.
Laboratory assays
A heparin blood sample (5 ml) was collected between 800 
and 900 a.m. to avoid circadian fluctuations of the para-
meters studied following the Mobil-Graph Units for non-
-invasive 24-hour blood pressure monitoring.
The CRP level in plasma was assessed with enzyme-lin-
ked immunosorbent assay (ELISA) using MP Biomedicals’ 
High Sensitivity C-Reactive Protein Enzyme Immunoassay 
Test Kit according to the manufacturer’s instructions. All of 
the mentioned parameters were analyzed before and after 
four weeks of treatment.
Statistics
Results were expressed as the mean +/–SD. The normality 
of distribution was checked by means of the Kolmogorov-
Smirnov test. The statistical evaluation was performed using 
analysis of variance (ANOVA) and post hoc comparison 
was conducted by means of the Newman-Keuls test. In 
the case of non-normally distributed data, statistical eva-
luation was performed by Kruskal-Wallis and Dunn’s te-
sts. Comparison of parameters before and after therapy in 
the same group was investigated with the Wilcoxon test. 
The correlation between CRP level and systolic and dia-
stolic blood pressure was calculated using Spearman’s me-
thod. All statistical analyses were conducted using Graph 
Pad Prism 4.0 and Statistica 6.0. A p-value of <0.05 was 
considered significant.
Institutional Review Board
The Local Review Board (Medical University of Silesia, 
Katowice, Poland) accepted the study protocol.
results
Drug therapies were not associated with any serious ad-
verse effects. Two patients treated with perindopril (one 
with mild hypertension, another with moderate hyperten-
sion) reported cough at the end of the study period. In the 
bisoprolol-treated group two patients suffered from fati-
gue and one from bradycardia (<50 bpm during the day). 
All patients, excluding those mentioned above, continued 
the treatment after the end of the study period.
24 h blood pressure monitoring
The measurements were taken and evaluated according to 
the ESC-ESH guidelines (2007). In the group with mode-
rate hypertension the four-week combined therapy resul-
ted in a decrease of all measured blood pressure parame-
ters, both systolic and diastolic (Table 2).
There was no alteration in the ratio between day and night 
pressure drop. Blood pressure values in mild hypertensive 
Parameters Control group Study groups
Number of patients 30
67
22 22 23
Hypertension N/A Moderate Mild Mild
Male/Female 17/13 12/10 12/10 12/11
Mean BMI (kg/m2) 25.5±2.2 25.5±2.5 25.6±2.1 25.0±3.1
Mean age (years) 43.6±9.2 45.7±8.2 44.1±8.2 46.2±11.7
Perindopril N/A 22 22 N/A
Bisoprolol N/A 22 N/A 23
Table 1. Patients characteristics
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derate hypertension, but still met all criteria of ESC-ESH. 
Beta-blocker therapy resulted in significantly lower mean 
blood pressures (diastolic and systolic pressure) during a 
twenty-four-hour period as well as during waking hours. 
The decrease in night values (diastolic and systolic) was not 
significant. Corresponding results were noted in an ACE 
inhibitor treated group. Both hypertension therapies were 
similarly effective, except for the considerably greater re-
duction of mean diastolic pressure during the day period 
by perindopril (79.8 vs. 82.8 mmHg; p=0.017).
Plasma CRP level
The baseline CRP level correlated with the increase of 
blood pressure in a linear manner. At the beginning of the 
study the level of CRP did not statistically differ betwe-
en control subjects and patients with mild hypertension. 
In patients with moderate hypertension the difference re-
ached statistical significance in relation to the control gro-
up (p<0.001) as well as to the mild hypertension group 
(p<0.04) (Table 3).
Following the antihypertensive therapy, a progressive re-
duction in CRP level was observed. In patients with mo-
derate hypertension the decrease reached 28% (p=0.03) 
but even then it was higher than in control subjects. The 
bisoprolol treatment was associated with a CRP decrease 
reaching 35% (p<0.001) while the perindopril therapy de-
creased it insignificantly by 22% (Table 3).
The comparison of both groups with mild hypertension 
did not reveal any differences in initial plasma CRP level 
(p=0.91). The extent of CRP level reduction in the perin-
dopril-treated group was analogous to the bisoprolol-tre-
ated group.
Correlation analysis
Correlation analysis revealed an association between ini-
tial CRP level and the mean 24-hour systolic blood pres-
sure (r=0.32, p=0.02) (Table 4).
Correlation coefficients for mean day and night systolic 
pressure with CRP level did not reach statistical significance.
Hypertension stage 2 Hypertension stage 1
Treatment Perindopril + bisoprolol Perindopril Bisoprolol
Before After Before After Before After
Mean 24-hour systolic 
pressure/mmHg/ Mean+/–SD 144.3±5.1  119.4±8.3*  137.4±13.4  121.6±10.0**  136.7±10.4  124.6±9.0**
Mean 24-hour diastolic 
pressure/mmHg/ Mean+/–SD 90.2±3.2  73.9±5.8*  86.3±10.1  78.3±6.1***  82.7±5.9  78.6±5.3**
Mean day systolic 
pressure/mmHg/ Mean+/–SD 149.7±5.2  122.8±7.9*  145.0±13.4  124.9±10.1*  141.5±11.4  130.1±11.3**
Mean day diastolic 
pressure/mmHg/ Mean+/–SD 93.5±3.7  76.4±5.1*  90.6±10.4  79.8±6.6*  86.4±6.8  82.8±6.0***
Dipper (drop percentage 
day/night) Mean+/–SD 10.2±5.6  11.7±7.4  16.3±7.7  9.7±7.5  11.8±6.1  10.5±4.5
Table 2. Values of blood pressure before and after therapy
* p<0.001, ** p<0.01, *** p<0.05.
Parameters Control group Study groups
Hypertension N/A Moderate (combined therapy) Mild (bisoprolol) Mild (perindopril)
CRP before therapy 1.42±0.85 2.55±1.28 2.04±1.36 1.99±1.3
CRP after therapy N/A 1.84±1.3 1.35±0.92 1.56±1.29
p (before vs. after) N/A 0.03 0.001 ns
p (after vs. control group) N/A 0.001 ns ns
p (before vs. control) N/A <0.001 ns ns
Table 3. The CRP level (mg/L) in the control and study groups
CRP Mean day 
systolic pressure
Mean night 
systolic pressure
Mean 24-hour 
systolic pressure
r 0.25 0.254 0.32
p 0.077 0.075 0.02
Table 4. Correlation coefficients for CRP and systolic pressure
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The obtained results revealed that hypertension is asso-
ciated with the intensified function of the immune system, 
corresponding to an increased CRP level. Our study com-
pared head-to-head effects of monotherapies with perin-
dopril and bisoprolol as well as combined therapy. We ob-
served similar effects on blood pressure associated with 
monotherapies and superior efficiency of combined thera-
py. The CRP level is thought to be an independent factor 
of increased mortality. The JUPITER study showed that 
mortality may be reduced by treatment with agents (statins) 
reducing the CRP level [29]. We noted that an increase of 
blood pressure is accompanied by an elevated CRP level. 
During the treatment significant reductions of CRP level 
were observed. Nevertheless, the CRP level did not drop 
after 30 days of therapy to the level seen in healthy subjects.
In the past few years the significant role of CRP in athero-
sclerosis has been confirmed. CRP increases the expres-
sion of adhesive molecules and chemokines on endothelial 
cells [27] as well as LDL uptake by macrophages [14,15,42], 
not to mention the raising of the AT-1 receptor expression 
on smooth muscle cells [40]. Furthermore, CRP inhibits 
nitric oxide synthase (NOS), and increases release of en-
dothelin-1, resulting in endothelium dysfunction [38,39]. 
In those cases the CRP acts mainly through a specific Fc-
gamma receptor, leading to a decrease in NOS activity and 
prostacyclin levels and an augmented expression of adhe-
sion molecules (e.g. ICAM-1 and VCAM-1) [10].
The increased level of CRP correlates with myocardial in-
farction severity and its complications [1] together with en-
dothelial cell dysfunction and the risk of acute coronary 
syndromes (ACS) in patients with stable angina [12,13,16] 
as well as in patients with ACS without ST-elevation [23]. 
The assessment of CRP level in patients with stable an-
gina is recommended by the American Heart Association 
guidelines for cardiac risk evaluation. There are three ran-
ges (<1.0, 1.0–3.0 and >3.0 mg/L) that correspond to three 
risk categories: low, moderate and high [26].
The relation has also been confirmed in patients at risk of 
hypertension. A linear correlation was observed during 
eight-year follow-up in the WHS study between CRP le-
vel and the risk of hypertension development in the fu-
ture. The level of CRP was 30% higher in patients with 
high-normal blood pressure compared to healthy subjects 
[6]. The level of CRP ≥3.0 mg/L increased the risk of hy-
pertension development three-fold. Another study showed 
that a CRP level ≥3.0 mg/L increased the risk of hyperten-
sion by 79% only when coexisting with an increased body 
mass index (BMI) [19].
In our study, the level of CRP increased linearly with the 
BP. Those results appertain to the observations of Sesso 
et al. [31] along with the findings of Schillaci et al. [33] 
that revealed a correlation of CRP level with systolic va-
lues acquired during 24-hour blood pressure monitoring 
(r=0.28, p<0.001). No correlation was observed with dia-
stolic pressure values.
Following one month of antihypertensive therapy, the pre-
viously increased CRP levels in the mild hypertension 
groups (1.45 mg/L) had normalized. The CRP level in the 
moderate hypertension group had decreased, but still re-
mained 23% higher than in control subjects (1.84 vs. 1.42 
mg/L). The normalization of CRP appears to have been 
related to a decrease in BP.
There are only a few studies assessing the effects of anti-
hypertensive therapy with cardioselective beta-blockers on 
CRP in normolipidemic subjects. Yasunari et al. [41] repor-
ted the effect of six-month therapy with propranolol ver-
sus carvedilol on CRP level. The former did not lower the 
CRP level but the latter reduced it by 78%. King et al. [18] 
demonstrated the CRP-lowering properties of metoprolol 
in 75 hypertensive patients. The level of CRP was decre-
ased after one-month therapy, while another 2 months of 
therapy brought no further reduction. Recently, two studies 
have corroborated the reduction in CRP level during tre-
atment with drugs affecting the renin-angiotensin system 
(RAS). Nevertheless, there are also studies that have shown 
no effects on CRP level by antihypertensive treatment [22].
We did not observe a significant difference in the level of 
CRP between the bisoprolol group (1.35 mg/L) and the per-
indopril group (1.56 mg/L) at the end of the study. However, 
the magnitude of reduction was significantly greater after 
beta-blocker treatment. The positive effects of beta-bloc-
kers have been observed by others, including in patients 
with angina pectoris (CRP level =1.8 mg/L in beta-bloc-
ker treated group vs. 3.1 mg/L in other therapies) as well 
as in patients with heart failure (the CRP level was 37% 
lower in the beta-blocker group) [20].
The proinflammatory properties of angiotensin-2 result from 
the stimulation of AT-1 receptors that lead to the seconda-
ry activation of nuclear factor kappa B (NF-kB) and syn-
thesis of cytokines (MCP-1, Il-6, TNF-alpha, Il-1, PAI-1) 
in inflammatory, endothelial and vascular smooth muscle 
cells (4, 14, 17, 37–39). The angiotensin-2 augments the 
phospholipase C activation, leading to a higher intracellu-
lar calcium level and endothelin-1 release [5].
Considering all of these facts, the angiotensin-converting 
enzyme inhibitors are believed to lower the CRP level in 
hypertension. The study by Mitrovic et al. [22] demonstra-
ted a decrease in CRP level after 3-month therapy with ra-
mipril in patients with atherosclerosis. Also in the MESA 
study [26] this beneficial effect was observed, while the 
Trandolapril Cardiac Evaluation (TRACE) study found 
no influence on CRP level in patients with myocardial in-
farction [7]. Similarly, enalapril did not affect the CRP le-
vel in patients with angina pectoris or after an acute coro-
nary episode [30,37]. Monotherapy with ramipril reduced 
the CRP level in diabetic (by 24%) and atherosclerotic (by 
32%) patients [22] but no effect in diabetic and hyperten-
sive patients was observed after treatment with lisinopril 
[32]. The prospective multi-center study by Di Napoli and 
Papa [11] showed that treatment with ACE-I lowered the 
CRP level 2.6-fold and reduced the risk of recurrent ce-
rebral stroke.
One of the limitations of our study was the relatively small 
sample size due to strict inclusion criteria. However, as 
a result a high degree of homogeneity in treated groups 
was obtained.
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at least partly depends on blood pressure values. A linear 
correlation between CRP and blood pressure was revealed. 
Reduction in blood pressure values after antihypertensive 
therapy and the lack of statistical differences between per-
indopril and bisoprolol treated groups might suggest that 
the CRP-lowering effect of those medications depends on 
their influence on blood pressure. The blood pressure nor-
malization is followed by a decrease of CRP level, which 
might in turn be reflected in better cardiovascular outco-
me in the future (Table 5).
What is known about topic What this study adds
• Hypertension is accompanied by an increased CRP level
• Elevated CRP level is a known cardiovascular risk factor
• Antihypertensive therapies reduce CRP level
•  A head-to-head comparison of the effects of a selective beta blocker 
(bisoprolol) vs. a commonly used ACE-I (perindopril)
•  Beneficial effects of the combined therapy compared to monotherapies 
(but not normalization of CRP)
Table 5. Summary of the study
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